PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers. The role of PARP1 in cervical cancer (CC) resistance and implication of PARP inhibitor is yet to be elucidated. Our data demonstrates significantly higher expression of PARP1 in primary cervical tumors and CC cell lines SiHa and ME180. Upon cisplatin treatment CC cells display significant overexpression of PARP1 and its hyperactivation. PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. PARP inhibited cells show delay in resolution of γH2A.X foci and prolonged late S and G2-M phase arrest resulting in apoptosis. Further, PARP inhibition disrupts the localization of base excision repair (BER) effector XRCC1 and non-homologous end joining (NHEJ) proteins Ku80 and XRCC4. Due to disrupted relocation of repair factors, cisplatin induced stalled replication forks collapse and convert into double strand breaks (DSBs). Interestingly, PARP inhibition also shows anti-migratory and anti-invasive properties in CC cells, increases anchorage independent cell death and induces anoikis. Collectively, our data demonstrates therapeutic potential of PARP inhibitor in cervical cancer.
Among all the 17 members of PARP family, PARP1 is one of the most abundant proteins which is involved in regulation of transcriptional control, maintenance of genomic integrity, DNA repair and regulation of apoptotic and survival balance in cells1,2. PARP1 is abundantly localized in nucleus and 80% of its enzymatic activity includes PARylation of nuclear proteins, recruitment of DNA repair factors and stabilization of chromatin for transcriptional regulation3. In past 4 decades several potent PARP inhibitors have been discovered and clinically investigated as chemotherapeutic agent for the treatment of cancers with inherent defect in their DNA repair pathways4. Several PARP inhibitors including Olaparib (AZD2281), Niraparib (MK-4827), Veliparib and BMN673 have been identified as potential chemotherapeutic agents. These pharmacological inhibitors have shown antitumor activity alone or in combination with platinum based therapeutic agents in several cancers with DNA repair defects including ovarian5,6,7,8 and breast cancers7,8,9. Olaparib has been demonstrated to exert anticancer property in BRCA1 or BRCA2 deficient breast cancer8,10, loss of ERCC1 and synergistic interaction with cisplatin in non-small cell lung carcinoma11,12,13, ATM depletion in breast cancer14, MRE11 loss in endometrial cancer15 and defect in homologous recombination16,17. Olaparib also tends to increase oncolytic activity of dl922-947 in a model of anaplastic thyroid carcinoma18. Contribution of PARP1 in regulation of metastatic events has also been thoroughly investigated in DNA repair independent manner in lung cancer via S100A4 and in melanoma via regulation of vimentin expression19,20,21. Recent phase I trial of PARP inhibitor in combination with cisplatin and paclitaxel shows well tolerance and promising results in both persistent and recurrent cervical cancer22.
Platinum based chemotherapeutic agents are the mainstream treatment line for most of the solid tumors. Platinum resistance is one of the biggest hurdles in successful treatment of tumors. Several lines of evidence reveal that PARP is responsible for platinum resistance in cancer23. PARP1 is able to detect DNA strand nicks and binds to it. After binding with DNA strand PARP1 undergoes PARylation and detach from the DNA, olaparib inhibits the auto-modification of PARP1 and traps it on the DNA strand causing inhibition of its enzymatic activity24. PARP1 trapping at damaged DNA strand inhibits the recruitment of DNA repair enzymes at the site leading to creation of persistent double strand breaks (DSBs) in DNA which is more lethal compared with depletion of PARP protein25. PARP plays potential role in regulation of homologous recombination (HR) and NHEJ26,27, competes with Ku70/80 for DNA binding in NHEJ pathway28 and regulation of XRCC1 recruitment during oxidative stress and other genomic insults29,30.
Our results suggest that PARP inhibition by olaparib and its combination with cisplatin has profound anticancer effect and anti-metastatic effect and may be used as therapeutic strategy in treatment of advanced cervical carcinoma.
CC cells exhibit higher amount of PARP1
We investigated the expression pattern of PARP1 in CC cell lines and primary tissue samples using quantitative real-time PCR and western blot analysis from total RNA and protein respectively. Our results show significant upregulation of PARP1in tumor samples and in CC cell lines compared with normal cervical tissue both at transcript and protein levels. PARP1 protein is also highly expressed in IIB and IIIB stages of the tumor in comparison to IIA stage. Advancement of the disease from IIB to IIIB displayed trend of upregulation in PARP1 expression, however the difference is not significant (Fig. 1A–C). CC cell lines SiHa and ME180 showed nuclear accumulation of PARP1 foci (Fig. 1D). Next, we investigated PARP1 expression pattern in pre-chemotherapeutic, formalin fixed samples from CC patients. PARP1 found to be express in primary tumors and have greater nuclear intensity in IIIB samples than IIB samples, however normal sample show a little expression in nucleus (Fig. 1E).
Cisplatin mediated replication stress trigger PARP1 over-expression & hyperactivation in CC cell lines
We and others have previously shown that platinum-DNA adduct formation by cisplatin treatment causes significant replication stress in CC cells as well as in other cancer cell types31,32,33. Replication stress caused by cisplatin triggered overexpression of PARP1 in both the SiHa and ME180 cell lines at transcript and protein levels (Fig. 2A and B). Cisplatin treatment also triggers the hyperactivation of PARP1 which was measured by detection of PAR polymers. In order to assess the kinetics of PARP1 overexpression and PAR formation, CC cells were incubated with two different concentrations (5 µM and 10 µM) of cisplatin for 48 hrs or for indicated time points (3, 6, 12, 24 hrs) and expression of PARP1 and PAR was determined by western blot analysis. PARP1 is overexpressed and activated in response to cisplatin dose- dependently. Time dependent formation of PAR was also evaluated simultaneously in CC cell lines. Cisplatin causes PARP1 hyperactivation in both SiHa and ME180 cell lines. PAR polymers formation was started as early as after 3 hr treatment of cisplatin. The level of PAR polymers increases with cisplatin concentration and treatment duration (Fig. 2C). Similarly, depletion of PARP1 with specific siRNA was also able to reduce basal PARP1 protein level as well as cisplatin induced protein elevation of PARP1 in both the cell lines (Fig. 2D). SiHa and ME180 cell lines also show higher nuclear accumulation of PARP1 foci after cisplatin treatment (Fig. 2E). Elevation in PAR polymer level clearly indicates the hyperactivation of PARP1 in CC cells in response to replication stress caused by platinum-DNA adduct.
Effect of Olaparib on cisplatin mediated hyperactivation of PARP1
Earlier reports indicate the involvement of PARP1 hyperactivation in cisplatin resistance in other tumor types.To determine the effect of olaparib on PARP1 activity, CC cells were treated with cisplatin along with two different concentrations (5 µM and 10 µM) of olaparib. Results demonstrate that olaparib treatment was sufficient to inhibit cisplatin induced formation of PAR polymers (Fig. 3A and B). PARP1 hyperactivation was also confirmed with immuno-staining of PAR polymers in cells which show significant nuclear accumulation in cisplatin treated cells than untreated cells. PAR polymer formation was completely suppressed by olaparib in cisplatin treated cells in both the cell lines. Similarly, PARP1 siRNA transfected cells show inhibition of PAR formation in response to cisplatin (Fig. 3C). PARP1 inhibited or silenced cells in combination with cisplatin exhibit profound DNA damage and produce more numbers of γH2A.X+ PAR− cells compare to γH2A.X+ PAR+ cells produced by cisplatin alone. CC cells treated with combination of cisplatin and olaparib displayed higher number of γH2A.X foci than single agent (Fig. 3D)
Olaparib increases cisplatin induced lethality in CC cells
An earlier report shows that PARP inhibitors trap PARP1 molecules at the site of DNA damage and inhibit its detachment from DNA strand24. SiHa and ME180 cells were treated with indicated concentrations of cisplatin or olaparib alone for 72 hrs and cell proliferation was estimated using MTT assay. Cell proliferation assay showed that cisplatin and olaparib inhibit cell proliferation significantly at higher drug doses (Fig. 4A). Since CC cells produce more PARP1 in response to cisplatin, we introduced PARP inhibitor along with cisplatin to trap more PARP1 molecules at DNA damage sites. Cells treated with cisplatin (10 µM) and olaparib (10 µM) show significant inhibition of cell growth than cells treated with a single drug. Further, cisplatin was also combined with two different doses (5 µM and 10 µM) of olaparib and cell proliferation was investigated after 72 hrs of treatment. Combination of drugs was able to inhibit cell proliferation more potentially than a single drug (Fig. 4B). Similarly, prolonged clonogenic survival also displayed that cisplatin-induced loss of clonogenic survival was increased by simultaneous treatment of olaparib in both the CC cell lines (Fig. 4C). Combination of Cisplatin and Olaparib did not show significant increased inhibition of cell survival in HEK239 cells (Supplementary Figure S1). Results suggest that olaparib trap higher amounts of PARP1 induced by cisplatin and simultaneously exert enhanced lethality in CC cells.
PARP inhibition collapses cisplatin induced stalled replication fork and produce more DSBs
Platinum salt based therapeutic agents are well known for their replication stress via formation of platinum-DNA adducts in dividing cells. Therefore, we investigated the potential of PARP1 inhibition and progression of replication fork caused by therapeutic agent cisplatin. Replication protein A (RPA) binds to single stranded DNA (ssDNA) and actively facilitates the replication. RPA foci serve as marker for active replication fork as well as ssDNA. Cells were treated with cisplatin and/or olaparib for 24 hrs and number of RPA foci was observed in both the groups. Cells treated with cisplatin show significantly higher RPA foci which were relocated at replication fork stalled sites. Cisplatin induced RPA foci were significantly lower in PARP1 inhibited cells but cells exhibit higher number of γH2A.X foci. Similarly, PARP1 depleted cells also show reduced number of RPA foci and higher number of γH2A.X foci after cisplatin treatment (Fig. 5A and B). This suggests the active role of PARP1 in formation of ssDNA and active replication fork. PARP1 inhibited and silenced cells show rapid induction of γH2A.X foci and complete relocation of DSB repair effector 53BP1 foci at damage sites. Cells treated with either cisplatin or olaparib displayed less number of γH2A.X and 53BP1 foci than the combined treatment. DNA damage induced by cisplatin in PARP1 inhibited or silenced background produces higher number of 53BP1 foci and display higher number of cells positive for γH2A.X+53BP1+ (Fig. 5C and D).
PARP1 inhibition/silencing enhances cisplatin sensitivity in CC cells and rapid induction of DNA damage
To assess the DNA damage capability of cisplatin in PARP1 inhibited cells, CC cell lines were treated alone or in combination with both the drugs. Combined treatment was able to produce higher number of cells positive for γH2A.X signals than either of the single drug. PARP inhibitor olaparib significantly exacerbated cisplatin induced DNA damage in CC cells. Cells with positive γH2A.X foci were not significant after 24hr of treatment since there were more frequent DNA damage sites in the cells (Fig. 6A). Similarly, PARP1 silenced SiHa and ME180 cells show rapid induction of γH2A.X foci (Fig. 6B). PARP1 silenced CC cells and scrambled counterparts were exposed to different concentration of cisplatin for 72 hrs. Cell proliferation assay displayed significant reduction in cell survival in PARP1 depleted cells.
PARP1 inhibited cells display significant delay in DNA repair and cell cycle progression
DNA repair kinetics was carried out for 10 days after single or combined treatment with cisplatin (10 µM) and/or olaparib (10 µM) for 24 hrs. Both cell lines were exposed to drugs for 24 hrs and drugs were removed (DR); at time point 0 (DR0) cells were fixed and cells were observed for γH2A.X foci every 24 hrs till 10 days (DR0 to DR10). The frequency of cells with γH2A.X foci was counted in all three groups in both the cell lines. After 24 hrs of drug treatment, frequency of γH2A.X foci increased in all the three groups. 70–80% of the cells had more than 20 foci regardless of drug treatment groups. After drug removal there was no significant difference in resolution of γH2A.X foci till 48 hrs. In contrast, PARP1 inhibited cells treated with cisplatin show significant delay in γH2A.X foci resolution than either olaparib or cisplatin treatment [Time point DR3, frequency of cells with more than 20 foci per cell in SiHa; cisplatin vs. cisplatin + olaparib p = 0.0467, at DR4; cisplatin vs. cisplatin + olaparib p = 0.0268, at DR5; cisplatin vs. cisplatin + olaparib p = 0.0060 and frequency of cells with more than 20 foci per cell in ME180 at DR3; cisplatin vs. cisplatin + olaparib p = 0.0390,at DR4; cisplatin vs. cisplatin + olaparib p = 0.041, at DR5; cisplatin vs. cisplatin + olaparib p = 0.0024]. PARP1 inhibited cells fail to resolve the global DNA damage induced by cisplatin in both the cell lines even after 10 days of drug removal (Fig. 7A and Supplementary Figure S2). Total cells with γH2A.X foci were also analyzed in same experimental condition in both the cell lines. Cells were co-stained with PI and FITC tagged γH2A.X and 10,000 cells were acquired by flow cytometer. PARP1 inhibited cells showed significant amount of DNA damage in every phase of cell cycle in time course analysis of DNA repair. Combined treatment shows increased DNA lesions in late S and G2/M phase than G1 phase (Fig. 7B and Supplementary Figure S3). We also assessed the DNA repair capacity of PARP silenced cells in both the cell lines. We exposed both PARP1 silenced and control cells to 5 μM cisplatin for shorter duration (3 hr) and then drug was replaced with drug free medium and cells were analyzed for γH2A.X foci resolution. PARP1 silenced cells failed to repair DNA damage and show significant delay in resolution of γH2A.X foci than the cells transfected with scrambled siRNA (Fig. 7C and Supplementary Figure S4).
We also investigated the cell cycle response of cisplatin and/or olaparib treated SiHa and ME180 cells. As described in previous experiments, cells were treated with either single drug or in combination of drugs and were analyzed for cell cycle in flow cytometer. Although, cisplatin and olaparib both were able to arrest the cell cycle in G2/M phase as single agent, PARP1 inhibition in DNA damage background exert profound and prolonged cell cycle arrest in late S and G2/M phase (Fig. 7D and Supplementary Figure S5).
PARP1 inhibition interferes with recruitment of BER effector XRCC1 and NHEJ mediators XRCC4 and KU80 at DNA damage sites
We further investigated the result of PARP1 trapping at chromatin and its effect on BER effector XRCC1 and NHEJ mediators Ku80 and XRCC4 recruitment at DNA damage site. Co-immunofluoresence of γH2A.X was carried out with PARP1, XRCC1, XRCC4 and Ku80 in cisplatin, cisplatin + olaparib and PARP siRNA transfected CC cells treated with cisplatin. BER effector XRCC1 requires active PARP1 to be recruited at DNA damage sites and PARP inhibitors induces apoptosis in XRCC1 dependent manner29,30. We investigated the recruitment of XRCC1 in PARP1 inhibited CC cells. PARP inhibitor significantly reduces the XRCC1 foci formation and disrupts the relocation of XRCC1 at γH2A.X foci in CC cells. Similarly, PARP1 silenced cells also displayed disruption of XRCC1 relocation at damage site and significantly show lower number of XRCC1 foci (Fig. 8A and B). This suggests that presence of PARP1 protein as well as its activation is critical for XRCC1 recruitment at DNA damage sites. However, specific depletion of PARP1 with siRNA did not alter the relocation of XRCC4 and KU80 at damage sites but the trapping of PARP with olaparib significantly reduces the relocation of NHEJ mediators at DSBs sites (Fig. 8C–F). Since both PARP1 and KU80 proteins have high competition for DNA end binding, PARP1 trapping at DNA damage sites block the relocation and binding of NHEJ effectors resulting in sustained DSBs. Since PARP1 inhibited cells display enhanced DSBs, we further checked whether these DSBs act as substrate for HR mediated repair mechanism or not. Co-localization results show that the HR regulator RAD51 completely localizes with DSBs created by PAPR inhibition (Supplementary Figure S6).
PARP1 inhibition/silencing enhance cisplatin induced apoptosis in cervical cancer cells
We explored the apoptotic efficacy of PARP1 inhibition in CC cells. To test the role of PARP1 silencing or inhibition on apoptosis, cells were exposed to cisplatin and/or olaparib for 24 hrs and apoptosis assay was carried out by Annexin V/PI co-staining. Olaparib and cisplatin both were able to induce apoptosis in CC cells in dose dependent manner but the combination of both the drugs exerts significantly higher apoptosis (Fig. 9A and Supplementary Figure S7). Similarly, PARP1 silencing also made CC cells more sensitive towards cisplatin and exert increased apoptosis (Fig. 9B and Supplementary Figure S8).
PARP inhibitor suppresses metastatic events in CC
Several lines of evidence suggest that PARP regulates metastatic events in other cancers via pathway(s) independent of DNA repairs19,20,21. However, the role of PARP1 in CC metastasis is not documented yet. We investigated the effect of olaparib on metastatic events such as cell migration, invasion and anchorage independent cell survival of CC cells. Sub-lethal dose (IC50; 18.4 μM ± 1.5 μM for SiHa and 15.8 µM ± 1.2 µM for ME180) of olaparib (10 µM) displayed significant decrease in migration and invasion capacity of CC cell lines (Fig. 10A,B,C and D). To eradicate drug toxicity induced inhibition of cell migration and invasion, cells were stained with CFSE [(5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester)] stain and migration and invasion assay was performed. Healthy and live cells uptake CFSE and intracellular esterases cleave the acetate group resulting in green florescence. Olaparib treated cells show decrease in cell migration and invasion and was concordant with previous results and olaparib treated SiHa cells show decreased level of vimentin protein after olaparib treatment as well. (Supplementary Figure S9). This suggests that sub-lethal dose of olaparib was able to inhibit both migration and invasion of CC cells without altering cellular health or drug toxicity. Thereafter, effect of PARP inhibitor was investigated for targeting anoikis resistance. CC cell lines were cultured in both anchorage (adherent monolayer) and anchorage independent (suspension) conditions. Olaparib alone induces significant cell death in anchorage independent CC cells than adherent cells and promote significant apoptosis in suspension cells than in adherent CC cells (Fig. 10E and F and Supplementary Figures S10 and S11).
One of the major challenges in the era of cancer treatment is the identification of the pathways or genes involved in the development of resistance to conventional therapies i.e., radio-resistance or chemo-resistance. Although, some reports have identified some of the pathway(s) and molecular mechanisms responsible for cisplatin resistance in several cancers including CC, a comprehensive mechanism(s) is largely unclear34,35,36,37,38,39,40,41. Several markers have already been identified that collaborate with PARP inhibitor sensitivity in cancer cells42,43,44. Here, we have provided insight of molecular mechanism by which PARP inhibitor potentially collaborates with cisplatin in CC cells and exert anticancer response. We hypothesized that combination of olaparib with cisplatin could enhance the efficacy of cisplatin in CC and help in improvement of platinum based therapy in CC. Our expression profile data of PARP1 demonstrates significantly increased expression in primary cervical cancer tissue biopsies and CC cell lines (Fig. 1). There are only two reports that have shown higher activity of PARP and its expression in CC compared to normal tissue in limited experiments but they have not provided any molecular mechanism of the contribution of PARP in CC cells45,46. Olaparib inhibits the PARylation of DNA bound PARP and its dissociation from the DNA strand and inhibits its enzymatic activity. Therefore, the presence of PARP molecule is critical for the action of PARP inhibitors which is more lethal than depletion of PARP protein24,25,47. Similar to earlier report that PARP hyperactivation is linked with cisplatin resistance23, our results show PARP hyperactivation and overexpression after the cisplatin treatment suggesting contribution of PARP in cisplatin resistance in CC. PAR polymers vary in length from 16 to >60 ADP-ribose polymers, depending upon the amount of genomic stress48. Overexpression of PARP in cisplatin treated cells also shows formation of smaller PAR polymers in early treatment which gradually increases with the increasing duration or the drug concentration and subsequently it allowed us to implicate the action of olaparib, i.e., trapping of more PARP molecules in cisplatin treated cells. Our data also demonstrate that olaparib was able to inhibit cisplatin induced PARylation and exert enhanced DNA damage in CC cells (Figs 2 and 3). Several groups have already reported that olaparib potentially drive cisplatin efficacy in the cancers with or without DNA repair defective pathways12,49. Interestingly, olaparib was able to increase cisplatin induced loss of clonogenic survival (Fig. 4). The disruption of Fanconi Anemia-BRCA (FA-BRCA) pathway due to promoter hyper-methylation of FANCF in CC has already been shown50. FANC genes potentially participate in DNA repair mechanism induced by cisplatin or alkylating agents as normal cellular response51. FANCF interacts with BRCA1 and other proteins to initiate other cellular responses in the cancer cells51. Another finding demonstrates that deficiency of FANC genes sensitizes cancer cells to PARP inhibitors16. The potential anti-proliferative effects of olaparib in combination with cisplatin demonstrated in our results may be possibly due to inactivation of FA-BRCA pathway in CC. While both PARP depleted and PARP inhibited cells show sensitivity to cisplatin, PARP inhibited cells displayed enhanced sensitivity. RPA loss reportedly sensitizes the cells to PARP inhibitors and several therapeutic agents and enhanced cell death16,52. In line with earlier reports, we observed that both PARP depleted and inhibited CC cells display loss of RPA foci due to lack of PARP activity which regulate the recruitment of RPA via MRE11. Here in CC cells, both inhibition and depletion of PARP show lack of PARP activity and subsequent loss of RPA foci formation after cisplatin treatment. Inhibition of proper RPA recruitment results in open DNA ends and formation of DSBs and persistent 53BP1 recruitment. Similarly, cisplatin treated PARP silenced cells or cells treated with combination of drugs show increased numbers of 53BP1 foci as compared to single drug. Collectively, our data suggest that PARP inhibition leads to increased DSBs in replication stressed cells by collapsing replication fork (Figs 5 and 6).
PARP potentially participates in smooth progression of cell cycle and potentially promotes G2/M arrest compared with G1 following genotoxic stress53 and cisplatin is also documented for inducing checkpoint kinases and cell cycle arrest54,55. Our data show that olaparib or cisplatin alone is able to induce G2/M phase arrest. Remarkably, olaparib treatment in combination with cisplatin displayed enhanced effect and displayed prolonged cell cycle arrest and enhanced DSBs in late S and G2/M phase (Fig. 7). PARP is well documented for its role in SSBR/BER in co-operation with XRCC156,57,58, while some groups have also documented contradictory findings that PARP1 has no direct role in SSBR/BER pathway of DNA repair upon DNA damage59,60. Our results demonstrate that PARP inhibited and silenced CC cells show significant inhibition of XRCC1 recruitment at DNA damage sites. Data suggest that active PARP is required for completion of SSBR/BER. The reduction in XRCC1 foci in PARP inhibited cells results in accumulation of γH2A.X foci and subsequent conversion of SSB into double strand breaks (DSBs). PARP trapping potentially interferes with recruitment of several repair factors by creating steric hindrance around the DNA ends or by losing its enzymatic activity and loss of direct interaction with other proteins. Acetylation of PARP and other repair proteins displayed loss of PARP activity and it’s trapping at DNA ends61. A recent report also suggests that combination of PARP inhibitor with low dose of DNMT1 inhibitors increases PARP trapping at chromatin and induces enhanced cell death62. PARP displayed higher binding tendency to the DNA ends than KU70/80 and other damage sensors28. Our data suggest that PARP inhibition potentially decreases the relocation of KU80 and XRCC4 at damage ends by creating steric hindrance, whereas depletion of PARP has no such effect (Fig. 8). Trapping and silencing of PARP has no such effect on Rad51 recruitment as well. This data indicates that although PARP has no direct interaction with NHEJ effectors, its inhibition leads to the impairment of NHEJ pathway and enhanced DNA damage in CC cells. Production of more DSBs and failure of repair machinery in CC cells due to combined treatment of PARP inhibitor and cisplatin ultimately results in increased apoptosis and cell death (Fig. 9).
We also investigated the contribution of PARP in CC metastasis and its DNA repair independent functions. Previous studies have shown that PARP potentially regulates metastatic events like migration and invasion in other cancers19,20,21. Similarly, we have also demonstrated that olaparib treatment decreases vimentin expression in CC cells. We also demonstrate that sub-lethal dose of PARP inhibitor exerts significant anti-migratory and anti-invasive effect on CC cells and simultaneously decreases anchorage independent cell survival and induces apoptosis in CC cells by promoting anoikis as a single agent (Fig. 10).
Our study demonstrates that the disruption of PAR-γH2A.X association and loss of RPA results in formation of DSBs and persistent recruitment of 53BP1 in cervical cancer cells leading to subsequent cell cycle arrest and cell death. Inhibition of recruitment of broad spectrum DNA repair factors from different repair pathways i.e. BER and NHEJ contributes to failure of cisplatin induced DNA damage repair. Interestingly, our data also suggest the in-vitro anti-metastatic property of olaparib in cervical cancer cells, although it will need further in-vivo validation.
Methods and Materials
Cell culture and reagents
Human cervical cancer cell lines SiHa and ME180 were obtained from ATCC and maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 5% humidified CO2. PARP inhibitor Olaparib (AZD2281) was purchased from Selleckchem, Houston, USA. Cisplatin was purchased from Bio Vision, CA, USA. Anti-PARP antibody [clone 46D11, #9532 (WB 1:1000 and IF 1:800)], anti-vimentin [clone D21H3, #5741 (WB 1:1000)] and cell lysis buffer were obtained from Cell Signaling Technology, MA, USA. Anti-PAR antibody [#4336-APC-050 (WB 1:1200 and IF 1:400)] was purchased from Trevigen, MD, USA. Anti-γH2A.X (p-Ser139) antibody [clone EP854(2)Y, #ab81299 (IF 1:2000)] was purchased from Abcam, Alexa flour 488 anti-γH2A.X (phospho-S139) [clone 2F3, #613405 (IF 1:400 and FACS 1:200)] antibody was purchased from Bio Legend, San Diego, California and anti-GAPDH antibody [clone 2D4A7, #NB300–328 (WB 1:3000)] was obtained from Imgenex. XRCC4 (IF 1:200) and RPA (IF 1:400) antibodies were gifted by Dr. A.S. Balajee, Columbia University, New York, USA. XRCC1 (IF 1:500), 53BP (IF 1:500), RAD51 (IF 1:100) and Ku80 (IF 1:400) antibodies were kind gift from Dr. Sathees C. Raghavan, Indian Institute of Science, Bangalore.
Primary tumor biopsy and normal cervical tissue biopsy
Cervical cancer biopsies (n = 35; IIA (n = 3), IIB (n = 12), IIIB (n = 20) and normal cervical tissue (n = 15) (hysterectomy cases) were collected from Sir Sunderlal Hospital, Banaras Hindu University after written informed consent of the patients according to the approved protocol by institutional ethical committee of the Institute of Medical Sciences, Banaras Hindu University. Sample's inclusion or exclusion criteria were as described in Yadav et al.63. Briefly, normal cervical tissues were taken from the non-inflamed epithelial layer of ectocervix of patients undergoing hysterectomy due to either fibroid or prolapsed uterus. Ectocervix is the part of cervix which has squamous lining (glandular elements are present in the endocervix and at the squamocolumnar junction). Histology of normal samples and inflammation status was further confirmed by hematoxylin-eosin staining of tissue sections and samples having inflammation and glandular epithelium were excluded from the study. All the methods were performed in accordance with the relevant guidelines and regulations approved by institutional ethical committee.
Cells were plated in 12 well plated in antibiotic free medium. 70–80% confluent cells were subjected to transfection. PARP siRNA and non-specific control siRNA were purchased from Santa Cruz Biotechnology. Transfection was carried out using OptiMEMTM medium and LipofectamineTM 3000 regent (Invitrogen, CA, USA). Transfection was performed by mixing siRNA with Lipofectamine reagent in OptiMEMTM medium and cells were incubated with the complex for 12 hrs. After the transfection, medium was replaced with normal growth medium and experiments were carried out as required.
Cell viability assay
Cells were counted using Bio-Rad TC10 automated cell counter and 5 × 103 cells were seeded in 96 well plate(s) in triplicates and allowed to adhere overnight. Cells were incubated with cisplatin and/or olaparib with different concentrations or time. After treatment, cells were incubated with 6 mg/ml MTT solution and plates were further incubated in CO2 incubator for 3 hrs. After incubation, formazan crystals were dissolved in DMSO and plate(s) were scanned with BioRad iMark Microplate reader at 570 nm.
Clonogenic survival assay
Clonogenic survival was performed as previously describe64. Briefly CC cells were seeded in 6 well plates in very low density and allowed to adhere overnight. Next day cells were treated with drugs as indicated for 24 hrs. After 24 hrs, drugs were washed out and cells were grown in fresh growth medium for next 2 weeks. After formation of proper colonies (at least 50 cells/colony) in untreated cells, colonies were fixed into 4% paraformaldehyde and stained with 0.5% crystal violet and counted.
Protein extraction and western blot
Total protein was isolated from tissue and cell line using cell lysis buffer and protein quantity was determined via Bradford reagent. Equal amounts of protein was separated on SDS-PAGE and transferred to PVDF membrane. Membrane was then blocked with 5% non-fat milk in TBST for 2 hrs at room temperature (RT) and then hybridized overnight with specific primary antibody. After primary antibody incubation, membrane was washed 3 times with TBST and HRP labeled secondary antibody was added for 2 hrs at RT. Signal was detected using chemi-luminiscence on X-ray film.
Immunohistochemistry was done on paraffin embedded tissue sections which were mounted on poly L-lysine coated slides. Tissue sections were deparaffinized, dehydrated and treated for 10 minutes in citrate buffer for antigen retrieval in water bath at 95 °C. Sections were incubated in primary antibody diluted in blocking solution overnight at 4 °C. After incubation peroxidase conjugated secondary antibody was used against the primary antibody. For chromogenic detection, 3,3′-diaminobenzidine tetrahydrochloride (DAB) (Sigma, USA) was used as the substrate for peroxidase. Slides were counterstained with hematoxylin. Cells with brown nuclei were considered as positively stained for PARP1. Negative control experiment was performed without using primary antibody.
Cells were grown on cover slips in 12 well plates. Drug treatment was done as indicated in result sections. Upon completion of the treatments the cells were fixed in chilled methanol and blocked with blocking solution (1% BSA + 5% normal goat serum + 0.3M glycine and 0.01% Titron-X100) for 30 min at RT. Cells were then incubated with specific primary antibody or only with secondary antibody (isotype control) diluted in blocking solution and incubation was done in humid chamber at 4 °C overnight. After incubation, coverslip was washed 3 times with PBS and FITC or TRITC labeled secondary antibody was added for 2 hrs at RT. Cells were then washed and nucleus was stained with DAPI. Cell with more than 20 foci/cells were taken as positive for signal. Slides were scanned under scanning confocal microscope LMS780.
Cell cycle analysis
Cells were treated with cisplatin and/or olaparib as indicated in result section. After treatment, the cells were fixed with 70% chilled methanol for 2 hours at −20 °C. Cells were then washed with PSB and further incubated with RNaseA (250 μg/ml) in PBS for 2 hr at 37 °C and then stained with PI (1 mg/ml). Stained cells were analyzed using BD FACS caliber and analysis was done using Cell Quest Pro software.
Cells were grown in 6 well plates and treated with cisplatin and/or olaparib. After completion of the treatment the cells were harvested and washed with PBS 2 times. After washing cell were re-suspended in 200 µl 1× Annexin binding buffer containing PI and anti-Annexin-FITC antibody and cells were incubated at RT for 15 min in dark. After incubation stained cells were analyzed by BD FACS caliber in FL1 and FL2 channels. Data was analyzed using Cell Quest Pro software.
Multi-well plates were coated with Poly-Hema and cells were cultured in suspension condition as indicated in result section. After culture and drug treatment, cells were centrifuged and washed with PBS 2 times on ice. After washing, the cells were stained with PI (1mg/ml) for 15 min at RT and cells were analyzed by BD FACS caliber.
Transwell migration assay
Overnight serum starved cells were trypsinized and 20,000 cells were seeded in incomplete medium with or without drug in upper chamber of transwell insert. Insert was then placed in 24 well plates and lower part of the well was filled with 750 µl of medium supplemented with 10% FBS as chemo-attractant. The setup was then incubated in incubator for indicated duration. After incubation non migrated cells (cells in upper chamber) were removed by swapping with cotton swap and migrated cells were fixed with 4% paraformaldehyde, permeabilized with 100% methanol and stained with 0.5% crystal violet. After staining porous membrane was excised out and mounted on slide and migrated cells were photographed on Nikon 80i microscope. Several random fields were imaged and cells were counted in three independent experiments.
Transwell invasion assay
Invasion assay was performed similarly as migration assay except coating the insert with Basement Membrane Matrix (BMM) or Matrigel. Briefly, transwell insert was coated with BMM and allowed to solidify at 37 °C for 1 hr prior to cell seeding. 20,000 cells were then seeded on the top of the BMM with or without drug and cells were allowed to invade in BMM for indicated duration. After incubation for desired duration non-invaded cells were wiped out and invaded cells were fixed, stained and counted as described in migration assay.
All experiments were repeated three times until stated. Statistical analysis was done using Graph pad prism software Ver. 5.0.
D’Amours, D., Desnoyers, S., D’Silva, I. & Poirier, G. G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. The Biochemical journal 342(Pt 2), 249–268 (1999).
Ossovskaya, V. et al. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes & cancer 1, 812–821, https://doi.org/10.1177/1947601910383418 (2010).
Ba, X. & Garg, N. J. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. The American journal of pathology 178, 946–955, https://doi.org/10.1016/j.ajpath.2010.12.004 (2011).
Scott, C. L., Swisher, E. M. & Kaufmann, S. H. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 33, 1397–1406, https://doi.org/10.1200/JCO.2014.58.8848 (2015).
Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251, https://doi.org/10.1016/S0140-6736(10)60893-8 (2010).
Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England journal of medicine 366, 1382–1392, https://doi.org/10.1056/NEJMoa1105535 (2012).
Liu, J. F. et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. European journal of cancer 49, 2972–2978, https://doi.org/10.1016/j.ejca.2013.05.020 (2013).
Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244, https://doi.org/10.1016/S0140-6736(10)60892-6 (2010).
Dent, R. A. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast cancer research: BCR 15, R88, https://doi.org/10.1186/bcr3484 (2013).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917, https://doi.org/10.1038/nature03443 (2005).
Cheng, H. et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 34, 739–749, https://doi.org/10.1093/carcin/bgs393 (2013).
Michels, J. et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell cycle 12, 877–883, https://doi.org/10.4161/cc.24034 (2013).
Postel-Vinay, S. et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 32, 5377–5387, https://doi.org/10.1038/onc.2013.311 (2013).
Gilardini Montani, M. S. et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. Journal of experimental & clinical cancer research CR 32, 95, https://doi.org/10.1186/1756-9966-32-95 (2013).
Koppensteiner, R. et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PloS one 9, e100041, https://doi.org/10.1371/journal.pone.0100041 (2014).
McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer research 66, 8109–8115, https://doi.org/10.1158/0008-5472.CAN-06-0140 (2006).
Patel, A. G., Sarkaria, J. N. & Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proceedings of the National Academy of Sciences of the United States of America 108, 3406–3411, https://doi.org/10.1073/pnas.1013715108 (2011).
Passaro, C. et al. PARP inhibitor olaparib increases the oncolytic activity of dl922–947 in in vitro and in vivo model of anaplastic thyroid carcinoma. Molecular oncology 9, 78–92, https://doi.org/10.1016/j.molonc.2014.07.022 (2015).
Choi, E. B. et al. PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair. Oncogene 35, 4569–4579, https://doi.org/10.1038/onc.2016.3 (2016).
Chu, S., Xu, H., Ferro, T. J. & Rivera, P. X. Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells. American journal of physiology. Lung cellular and molecular physiology 293, L1127–1134, https://doi.org/10.1152/ajplung.00197.2007 (2007).
Rodriguez, M. I. et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS genetics 9, e1003531, https://doi.org/10.1371/journal.pgen.1003531 (2013).
Thaker, P. H. et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Annals of oncology: official journal of the European Society for Medical Oncology 28, 505–511, https://doi.org/10.1093/annonc/mdw635 (2017).
Michels, J. et al. Cisplatin resistance associated with PARP hyperactivation. Cancer research 73, 2271–2280, https://doi.org/10.1158/0008-5472.CAN-12-3000 (2013).
Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer research 72, 5588–5599, https://doi.org/10.1158/0008-5472.CAN-12-2753 (2012).
Godon, C. et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic acids research 36, 4454–4464, https://doi.org/10.1093/nar/gkn403 (2008).
Mansour, W. Y., Rhein, T. & Dahm-Daphi, J. The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. Nucleic acids research 38, 6065–6077, https://doi.org/10.1093/nar/gkq387 (2010).
Schultz, N. et al. Nucleic acids research 31, 4959–4964 (2003).
Wang, M. et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic acids research 34, 6170–6182, https://doi.org/10.1093/nar/gkl840 (2006).
Campalans, A. et al. Distinct spatiotemporal patterns and PARP dependence of XRCC1 recruitment to single-strand break and base excision repair. Nucleic acids research 41, 3115–3129, https://doi.org/10.1093/nar/gkt025 (2013).
El-Khamisy, S. F. et al. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic acids research 31, 5526–5533 (2003).
Das, M. et al. HPV-type-specific response of cervical cancer cells to cisplatin after silencing replication licensing factor MCM4. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 36, 9987–9994, https://doi.org/10.1007/s13277-015-3782-7 (2015).
Wagner, J. M. & Karnitz, L. M. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Molecular pharmacology 76, 208–214, https://doi.org/10.1124/mol.109.055178 (2009).
Cruet-Hennequart, S. et al. Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell cycle 8, 3039–3050 (2009).
Beskow, C. et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. British journal of cancer 101, 816–821, https://doi.org/10.1038/sj.bjc.6605201 (2009).
Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature reviews. Cancer 12, 587–598, https://doi.org/10.1038/nrc3342 (2012).
Brozovic, A. & Osmak, M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer letters 251, 1–16, https://doi.org/10.1016/j.canlet.2006.10.007 (2007).
Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869–1883, https://doi.org/10.1038/onc.2011.384 (2012).
Huang, E. Y. et al. A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell death & disease 3, e251, https://doi.org/10.1038/cddis.2011.120 (2012).
Kwok, J. M. et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Molecular cancer research: MCR8, 24–34, https://doi.org/10.1158/1541-7786.MCR-09-0432 (2010).
Martin, L. P., Hamilton, T. C. & Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clinical cancer research: an official journal of the American Association for Cancer Research 14, 1291–1295, https://doi.org/10.1158/1078-0432.CCR-07-2238 (2008).
Mehta, F. F., Baik, S. & Chung, S. H. Recurrence of cervical cancer and its resistance to progestin therapy in a mouse model. Oncotarget, https://doi.org/10.18632/oncotarget.13676 (2016).
Frankum, J. et al. Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget 6, 10746–10758, https://doi.org/10.18632/oncotarget.3628 (2015).
Oplustilova, L. et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell cycle 11, 3837–3850, https://doi.org/10.4161/cc.22026 (2012).
Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. The EMBO journal 27, 1368–1377, https://doi.org/10.1038/emboj.2008.61 (2008).
Fukushima, M. et al. Poly(ADP-ribose) synthesis in human cervical cancer cell-diagnostic cytological usefulness. Cancer letters 14, 227–236 (1981).
Hassumi-Fukasawa, M. K. et al. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathology oncology research: POR 18, 929–937, https://doi.org/10.1007/s12253-012-9523-y (2012).
Domagala, P., Lubinski, J. & Domagala, W. Iniparib in metastatic triple-negative breast cancer. The New England journal ofmedicine 364, 1780; author reply 1781, https://doi.org/10.1056/NEJMc1101855#SA1 (2011).
Andrabi, S. A. et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences of the United States of America 103, 18308–18313, https://doi.org/10.1073/pnas.0606526103 (2006).
Shunkwiler, L., Ferris, G. & Kunos, C. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair. International journal of molecular sciences 14, 3773–3785, https://doi.org/10.3390/ijms14023773 (2013).
Narayan, G. et al. Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer research 64, 2994–2997 (2004).
D’Andrea, A. D. & Grompe, M. The Fanconi anaemia/BRCA pathway. Nature reviews. Cancer 3, 23–34, https://doi.org/10.1038/nrc970 (2003).
Balajee, A. S. & Geard, C. R. Replication protein A and gamma-H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. Experimental cell research 300, 320–334, https://doi.org/10.1016/j.yexcr.2004.07.022 (2004).
Masutani, M., Nozaki, T., Wakabayashi, K. & Sugimura, T. Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Biochimie 77, 462–465 (1995).
Dasika, G. K. et al. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18, 7883–7899, https://doi.org/10.1038/sj.onc.1203283 (1999).
Roos, W. P. & Kaina, B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer letters 332, 237–248, https://doi.org/10.1016/j.canlet.2012.01.007 (2013).
Fisher, A. E., Hochegger, H., Takeda, S. & Caldecott, K. W. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Molecular and cellular biology 27, 5597–5605, https://doi.org/10.1128/MCB.02248-06 (2007).
Javle, M. & Curtin, N. J. The role of PARP in DNA repair and its therapeutic exploitation. British journal of cancer 105, 1114–1122, https://doi.org/10.1038/bjc.2011.382 (2011).
Orta, M. L. et al. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions. Nucleic acids research 42, 9108–9120, https://doi.org/10.1093/nar/gku638 (2014).
Strom, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic acids research 39, 3166–3175, https://doi.org/10.1093/nar/gkq1241 (2011).
Vodenicharov, M. D. et al. Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1. Nucleic acids research 28, 3887–3896 (2000).
Robert, C. et al. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. Leukemia research 45, 14–23, https://doi.org/10.1016/j.leukres.2016.03.007 (2016).
Muvarak, N. E. et al. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. Cancer cell 30, 637–650, https://doi.org/10.1016/j.ccell.2016.09.002 (2016).
Yadav, S. S. et al. Epigenetic silencing of CXCR4 promotes loss of cell adhesion in cervical cancer. BioMed research international 2014, 581403, https://doi.org/10.1155/2014/581403 (2014).
Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nature protocols 1, 2315–2319, https://doi.org/10.1038/nprot.2006.339 (2006).
Department of Biotechnology, Ministry of Science and Technology, Government of India for financial assistance (BT/PR9246/Med/30/17/2007) to G.N. and S.S.; and Department of Biotechnology, Ministry of Science and Technology, Government of India for Junior and Senior Research fellowships to CBP; Interdisciplinary School of Life Sciences, BHU and UGC-UPE, BHU for equipment facilities.
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Prasad, C.B., Prasad, S.B., Yadav, S.S. et al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 7, 12876 (2017). https://doi.org/10.1038/s41598-017-13232-3
Benzothiazole derivative bearing amide moiety induces p53-mediated apoptosis in HPV16 positive cervical cancer cells
Investigational New Drugs (2020)
Gamma ray-induced in vitro cell migration via EGFR/ERK/Akt/p38 activation is prevented by olaparib pretreatment
International Journal of Radiation Biology (2020)
Current Oncology Reports (2020)
PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade
Pathology & Oncology Research (2020)
MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer
Journal of Experimental & Clinical Cancer Research (2020)